Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study

By afschroeder • October 9, 2025

Papp KA, Jacobs S, Sofen H, Bukhalo M, Muscianisi E, Ma G, Lau G, Bettinger M, Rubio RG, Hitraya E, Blauvelt A; Open-Label Extension study team. Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study. J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02952-4. doi: 10.1016/j.jaad.2025.10.005. Epub ahead of print. PMID: 41061968.

Tags: Dermatology, durability, efficacy, envudeucitinib, ESK-001, long-term extension, Olive View DoM, phase 2, plaque psoriasis, Publications, safety, STRIDE, TYK2

Laboratory monitoring in patients with moderate to severe plaque psoriasis

Fenkel JM, Osborne JA, Armstrong AW, Strober B, Stein Gold L, Cameron M, Lebwohl M. Laboratory monitoring in patients with moderate to severe plaque psoriasis.[...]

Alopecia areata is associated with adverse pregnancy outcomes in a retrospective cohort study using TriNetX

Podolsky AS, Singal A, Goh C, Lipner SR. Alopecia areata is associated with adverse pregnancy outcomes in a retrospective cohort study using TriNetX. J Am[...]

Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L,[...]